Rigel's roller coaster ride of advances and setbacks continued this morning with the news that its drug fostamatinib failed a mid-stage study in IgA nephropathy, flunking the primary endpoint. Rigel's shares dropped 10% in the wake of the news.Apr 3, 2018
Is Rigl a good stock?
The financial health and growth prospects of RIGL, demonstrate its potential to underperform the market. It currently has a Growth Score of B. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.
Will Rigl go up?
Will Rigel Pharmaceuticals stock price grow / rise / go up? Yes. The RIGL stock price can go up from 2.400 USD to 2.418 USD in one year.
Who owns Rigel Pharmaceuticals?
Stockholder Stake Shares owned
--------------------------- ----- ------------
SSgA Funds Management, Inc. 5.09% 8,698,439
The Vanguard Group, Inc. 5.03% 8,606,861
Tamarack Advisers LP 4.09% 7,000,000
Invesco Advisers, Inc. 2.93% 5,014,000
Is Tavalisse FDA approved?
On , the US Food and Drug Administration (FDA) approved fostamatinib disodium hexahydrate (Tavalisse; Rigel Pharmaceuticals), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adults with chronic ITP who had an insufficient response to previous treatment.
Should I buy Rigel Pharmaceuticals stock?
Rigel Pharmaceuticals has received a consensus rating of Buy.